252 related articles for article (PubMed ID: 21248225)
21. Targeting the RAS-dependent chemoresistance: The Warburg connection.
Serna-Blasco R; Sanz-Álvarez M; Aguilera Ó; García-Foncillas J
Semin Cancer Biol; 2019 Feb; 54():80-90. PubMed ID: 29432815
[TBL] [Abstract][Full Text] [Related]
22. Kruppel-like factor 5 is not required for K-RasG12D lung tumorigenesis, but represses ABCG2 expression and is associated with better disease-specific survival.
Meyer SE; Hasenstein JR; Baktula A; Velu CS; Xu Y; Wan H; Whitsett JA; Gilks CB; Grimes HL
Am J Pathol; 2010 Sep; 177(3):1503-13. PubMed ID: 20639455
[TBL] [Abstract][Full Text] [Related]
23. Single copies of mutant KRAS and mutant PIK3CA cooperate in immortalized human epithelial cells to induce tumor formation.
Wang GM; Wong HY; Konishi H; Blair BG; Abukhdeir AM; Gustin JP; Rosen DM; Denmeade SR; Rasheed Z; Matsui W; Garay JP; Mohseni M; Higgins MJ; Cidado J; Jelovac D; Croessmann S; Cochran RL; Karnan S; Konishi Y; Ota A; Hosokawa Y; Argani P; Lauring J; Park BH
Cancer Res; 2013 Jun; 73(11):3248-61. PubMed ID: 23580570
[TBL] [Abstract][Full Text] [Related]
24. Proteogenomic Analysis of Single Amino Acid Polymorphisms in Cancer Research.
Garin-Muga A; Corrales FJ; Segura V
Adv Exp Med Biol; 2016; 926():93-113. PubMed ID: 27686808
[TBL] [Abstract][Full Text] [Related]
25. A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors.
Loboda A; Nebozhyn M; Klinghoffer R; Frazier J; Chastain M; Arthur W; Roberts B; Zhang T; Chenard M; Haines B; Andersen J; Nagashima K; Paweletz C; Lynch B; Feldman I; Dai H; Huang P; Watters J
BMC Med Genomics; 2010 Jun; 3():26. PubMed ID: 20591134
[TBL] [Abstract][Full Text] [Related]
26. The role of p19 and p21 H-Ras proteins and mutants in miRNA expression in cancer and a Costello syndrome cell model.
García-Cruz R; Camats M; Calin GA; Liu CG; Volinia S; Taccioli C; Croce CM; Bach-Elias M
BMC Med Genet; 2015 Jul; 16():46. PubMed ID: 26138095
[TBL] [Abstract][Full Text] [Related]
27. Genetically-defined metabolic reprogramming in cancer.
Mullen AR; DeBerardinis RJ
Trends Endocrinol Metab; 2012 Nov; 23(11):552-9. PubMed ID: 22858391
[TBL] [Abstract][Full Text] [Related]
28. Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability.
Umeda Y; Nagasaka T; Mori Y; Sadamori H; Sun DS; Shinoura S; Yoshida R; Satoh D; Nobuoka D; Utsumi M; Yoshida K; Yagi T; Fujiwara T
J Hepatobiliary Pancreat Sci; 2013 Feb; 20(2):223-33. PubMed ID: 23010994
[TBL] [Abstract][Full Text] [Related]
29. MEK activation modulates glycolysis and supports suppressive myeloid cells in TNBC.
Franklin DA; Sharick JT; Ericsson-Gonzalez PI; Sanchez V; Dean PT; Opalenik SR; Cairo S; Judde JG; Lewis MT; Chang JC; Sanders ME; Cook RS; Skala MC; Bordeaux J; Orozco Bender J; Vaupel C; Geiss G; Hinerfeld D; Balko JM
JCI Insight; 2020 Aug; 5(15):. PubMed ID: 32634121
[TBL] [Abstract][Full Text] [Related]
30. Use of multivariate analysis to suggest a new molecular classification of colorectal cancer.
Domingo E; Ramamoorthy R; Oukrif D; Rosmarin D; Presz M; Wang H; Pulker H; Lockstone H; Hveem T; Cranston T; Danielsen H; Novelli M; Davidson B; Xu ZZ; Molloy P; Johnstone E; Holmes C; Midgley R; Kerr D; Sieber O; Tomlinson I
J Pathol; 2013 Feb; 229(3):441-8. PubMed ID: 23165447
[TBL] [Abstract][Full Text] [Related]
31. A potent KRAS macromolecule degrader specifically targeting tumours with mutant KRAS.
Bery N; Miller A; Rabbitts T
Nat Commun; 2020 Jun; 11(1):3233. PubMed ID: 32591521
[TBL] [Abstract][Full Text] [Related]
32. The greedy nature of mutant RAS: a boon for drug discovery targeting cancer metabolism?
Lv J; Wang J; Chang S; Liu M; Pang X
Acta Biochim Biophys Sin (Shanghai); 2016 Jan; 48(1):17-26. PubMed ID: 26487443
[TBL] [Abstract][Full Text] [Related]
33. KRAS and BRAF: drug targets and predictive biomarkers.
Vakiani E; Solit DB
J Pathol; 2011 Jan; 223(2):219-29. PubMed ID: 21125676
[TBL] [Abstract][Full Text] [Related]
34. Identification of novel candidate biomarkers of epithelial ovarian cancer by profiling the secretomes of three-dimensional genetic models of ovarian carcinogenesis.
Lawrenson K; Mhawech-Fauceglia P; Worthington J; Spindler TJ; O'Brien D; Lee JM; Spain G; Sharifian M; Wang G; Darcy KM; Pejovic T; Sowter H; Timms JF; Gayther SA
Int J Cancer; 2015 Oct; 137(8):1806-17. PubMed ID: 25204737
[TBL] [Abstract][Full Text] [Related]
35. Expression of oncogene products, anti-oncogene products and oncofetal antigens in intraductal papillary-mucinous neoplasm of the pancreas.
Terada T; Ohta T; Nakanuma Y
Histopathology; 1996 Oct; 29(4):355-61. PubMed ID: 8910043
[TBL] [Abstract][Full Text] [Related]
36. Clinical outcomes and molecular profile of differentiated thyroid cancers with radioiodine-avid distant metastases.
Sabra MM; Dominguez JM; Grewal RK; Larson SM; Ghossein RA; Tuttle RM; Fagin JA
J Clin Endocrinol Metab; 2013 May; 98(5):E829-36. PubMed ID: 23533233
[TBL] [Abstract][Full Text] [Related]
37. Proteomic analysis of exosomes from mutant KRAS colon cancer cells identifies intercellular transfer of mutant KRAS.
Demory Beckler M; Higginbotham JN; Franklin JL; Ham AJ; Halvey PJ; Imasuen IE; Whitwell C; Li M; Liebler DC; Coffey RJ
Mol Cell Proteomics; 2013 Feb; 12(2):343-55. PubMed ID: 23161513
[TBL] [Abstract][Full Text] [Related]
38. Rationale for RAS mutation-tailored therapies.
Montalvo SK; Li L; Westover KD
Future Oncol; 2017 Feb; 13(3):263-271. PubMed ID: 27728979
[TBL] [Abstract][Full Text] [Related]
39. Increased expression of the heterogeneous nuclear ribonucleoprotein K in pancreatic cancer and its association with the mutant p53.
Zhou R; Shanas R; Nelson MA; Bhattacharyya A; Shi J
Int J Cancer; 2010 Jan; 126(2):395-404. PubMed ID: 19609950
[TBL] [Abstract][Full Text] [Related]
40. Epidermal growth factor receptor and K-RAS status in two cohorts of squamous cell carcinomas.
Van Damme N; Deron P; Van Roy N; Demetter P; Bols A; Van Dorpe J; Baert F; Van Laethem JL; Speleman F; Pauwels P; Peeters M
BMC Cancer; 2010 May; 10():189. PubMed ID: 20459770
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]